Rx-360 Names Mark Paxton as New CEO

October 27, 2015
Pharmaceutical Technology Editors

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and Management-11-04-2015, Volume 11, Issue 11

Rx-360 announced that Mark S. Paxton has been appointed as the new chief executive office of the international pharmaceutical supply chain consortium. This appointment follows the successful growth of Rx-360 since its foundation in 2009 in the aftermath of the adulterated heparin tragedy. Rx-360 has 300 volunteers from more than 100 institutions that are organized in 17 working groups with activities in the US, Europe, China, and India.

Rx-360 announced that Mark S. Paxton has been appointed as the new chief executive office of the international pharmaceutical supply chain consortium. This appointment follows the successful growth of Rx-360 since its foundation in 2009 in the aftermath of the adulterated heparin tragedy. Rx-360 has 300 volunteers from more than 100 institutions that are organized in 17 working groups with activities in the US, Europe, China, and India.

Paxton will lead the consortium and its membership in executing the Board’s Strategic Plan, expanding its membership and creating global awareness of Rx-360’s central mission-to protect patient safety by sharing information and developing processes related to the integrity of the healthcare supply chain and the quality of materials within the supply chain. Paxton comes to Rx-360 from FDA where he led an international Strategic Program focused on medical product quality and supply chain security under Asia-Pacific Economic Cooperation (APEC), a multi-lateral forum of governments to promote sustainable economic growth within the Asia-Pacific region.

Source: Rx-360